Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).
antiangiogenic treatments
lung cancer
squamous non-small cell
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
06
2019
accepted:
05
11
2019
entrez:
11
1
2020
pubmed:
11
1
2020
medline:
11
1
2020
Statut:
epublish
Résumé
Antiangiogenic agents have improved the prognosis of non-squamous non-small-cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor's characteristics or comorbidities. Much less information is available about the eligibility of patients with squamous non-small-cell lung cancers (SQ-NSCLCs) to receive antivascular endothelial growth-factor (VEGF) treatments, even though such molecules are being developed for this histology. This study was undertaken to determine the percentage of advanced SQ-NSCLC patients who would be eligible to receive an antiVEGF agent as second-line systemic therapy. This observational, multicenter, prospective study evaluated advanced SQ-NSCLC patients' criteria for ineligibility to receive an antiVEGF during a multidisciplinary meeting to choose their standard second-line systemic therapy. Among the 317 patients included, 53.6% had at least one ineligibility criterion, and ~20% had at least two, with disease extension to large vessels (39.8%), tumor cavitation (20.5%), cardiovascular disease (11%) and/or hemoptysis (7.2%) being the most frequent. Patients with an ECOG performance score of 1/2 had more cardiovascular contraindications that those with scores of 0. Almost half of the SQ-NSCLC patients included in this study would have been eligible to receive an antiVEGF agent. The development of these molecules for these indications should be encouraged.
Sections du résumé
BACKGROUND
BACKGROUND
Antiangiogenic agents have improved the prognosis of non-squamous non-small-cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor's characteristics or comorbidities. Much less information is available about the eligibility of patients with squamous non-small-cell lung cancers (SQ-NSCLCs) to receive antivascular endothelial growth-factor (VEGF) treatments, even though such molecules are being developed for this histology. This study was undertaken to determine the percentage of advanced SQ-NSCLC patients who would be eligible to receive an antiVEGF agent as second-line systemic therapy.
METHODS
METHODS
This observational, multicenter, prospective study evaluated advanced SQ-NSCLC patients' criteria for ineligibility to receive an antiVEGF during a multidisciplinary meeting to choose their standard second-line systemic therapy.
RESULTS
RESULTS
Among the 317 patients included, 53.6% had at least one ineligibility criterion, and ~20% had at least two, with disease extension to large vessels (39.8%), tumor cavitation (20.5%), cardiovascular disease (11%) and/or hemoptysis (7.2%) being the most frequent. Patients with an ECOG performance score of 1/2 had more cardiovascular contraindications that those with scores of 0.
CONCLUSION
CONCLUSIONS
Almost half of the SQ-NSCLC patients included in this study would have been eligible to receive an antiVEGF agent. The development of these molecules for these indications should be encouraged.
Identifiants
pubmed: 31920391
doi: 10.2147/CMAR.S219984
pii: 219984
pmc: PMC6938186
doi:
Types de publication
Journal Article
Langues
eng
Pagination
10821-10826Informations de copyright
© 2019 Vergnenègre et al.
Déclaration de conflit d'intérêts
A. Vergnenègre has received honoraria for consultancies and fees for medical conferences from MSD, Hoffman–La Roche, BMS, Pierre-Fabre Oncology, AstraZeneca, and Boehringer Ingelheim. Dr Olivier Bylicki reports personal fees from MSD, personal fees from ROCHE, personal fees from ASTRA-ZENECA, during the conduct of the study. The authors report no other conflicts of interest in this work.
Références
J Thorac Oncol. 2010 Sep;5(9):1416-23
pubmed: 20686429
J Thorac Oncol. 2018 Mar;13(3):301-322
pubmed: 29331646
J Thorac Oncol. 2011 Jan;6(1):109-14
pubmed: 21107290
Curr Oncol. 2018 Jun;25(Suppl 1):S45-S58
pubmed: 29910647
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Lancet Oncol. 2010 Aug;11(8):733-40
pubmed: 20650686
Lancet Oncol. 2014 Feb;15(2):143-55
pubmed: 24411639
Lung Cancer (Auckl). 2017 Dec 14;8:259-269
pubmed: 29276417
Oncotarget. 2016 Dec 13;7(50):82473-82481
pubmed: 27756883
J Clin Oncol. 2001 Feb 1;19(3):851-6
pubmed: 11157039
J Thorac Oncol. 2014 Sep;9(9):1332-9
pubmed: 25122429
Rev Mal Respir. 2012 Feb;29(2):161-77
pubmed: 22405111
Expert Opin Ther Targets. 2012 Apr;16(4):395-406
pubmed: 22439677
Ann Oncol. 2012 May;23(5):1111-1120
pubmed: 22056855
Lancet Oncol. 2010 Jul;11(7):619-26
pubmed: 20570559
Ann Oncol. 2010 Aug;21(8):1682-1686
pubmed: 20064831
BMC Cancer. 2015 May 01;15:339
pubmed: 25929582
Expert Opin Emerg Drugs. 2019 Jun;24(2):71-81
pubmed: 31092048
Drugs Real World Outcomes. 2016 Sep;3(3):333-343
pubmed: 27747837
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Future Oncol. 2017 Dec;13(28):2515-2535
pubmed: 28812378
Clin Lung Cancer. 2018 Sep;19(5):e783-e799
pubmed: 29983370
J Clin Oncol. 2004 Jun 1;22(11):2184-91
pubmed: 15169807
Eur J Cancer. 2020 May;131:27-36
pubmed: 32276179
J Clin Oncol. 2012 Sep 1;30(25):3084-92
pubmed: 22851564
PLoS One. 2015 Jun 02;10(6):e0127306
pubmed: 26034985
Lancet Oncol. 2015 Jul;16(7):763-74
pubmed: 26045340
J Clin Oncol. 2009 Mar 10;27(8):1227-34
pubmed: 19188680
Ann Transl Med. 2018 Apr;6(8):143
pubmed: 29862232
J Thorac Oncol. 2014 Feb;9(2):214-21
pubmed: 24419419
Drugs. 2014 Mar;74(4):403-13
pubmed: 24578213
Lung Cancer. 2017 Oct;112:181-187
pubmed: 29191593
J Thorac Oncol. 2012 Jan;7(1):212-8
pubmed: 22124474
J Cancer Res Clin Oncol. 2019 Oct;145(10):2555-2564
pubmed: 31350622
Ann Oncol. 2014 May;25(5):1044-52
pubmed: 24585722